by Touch Stone Publishers | Apr 21, 2026
On April 2, 2026, President Trump signed a presidential proclamation imposing a 100 percent ad valorem tariff on imported patented pharmaceuticals and their active pharmaceutical ingredients under Section 232 of the Trade Expansion Act of 1962. For boards at...
by Touch Stone Publishers | Apr 21, 2026
The technology sector’s strategic center of gravity has shifted from software scalability to physical infrastructure scarcity. In Q1 2026, energy availability emerged as the primary binding constraint on AI infrastructure expansion, signaling that boards...
by Touch Stone Publishers | Apr 21, 2026
On April 2, 2026, the White House imposed a 100 percent tariff on imports of patented pharmaceuticals and their active pharmaceutical ingredients under Section 232 of the Trade Expansion Act of 1962. For the 17 named companies listed in Annex III of the proclamation,...
by Touch Stone Publishers | Apr 20, 2026
President Trump’s April 2, 2026, Proclamation under Section 232 of the Trade Expansion Act of 1962 establishes a 100 percent ad valorem tariff on patented pharmaceutical products and their associated active pharmaceutical ingredients (APIs) imported into the...
by Touch Stone Publishers | Apr 16, 2026
The pharmaceutical sector entered a new regulatory epoch on April 2, 2026. President Trump’s Section 232 proclamation imposed tariffs of up to 100% on patented pharmaceutical imports and active pharmaceutical ingredients (APIs), citing national security grounds under...
